Cyclosporine for Recalcitrant Bullous Pemphigoid Induced by Nivolumab Therapy for Malignant Melanoma

Cutis. 2024 Jul;114(1):E21-E23. doi: 10.12788/cutis.1058.

Authors

Carly E Wallace¹, Idy Tam¹, Mara G Beveridge¹

Affiliation

¹ Dr. Wallace is from the Lake Erie College of Osteopathic Medicine, Bradenton, Florida. Drs. Tam and Beveridge are from the Department of Dermatology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Ohio.

PMID: 39159347
DOI: 10.12788/cutis.1058

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Agents, Immunological* / administration & dosage
Antineoplastic Agents, Immunological* / adverse effects
Cyclosporine* / administration & dosage
Cyclosporine* / adverse effects
Cyclosporine* / therapeutic use
Humans
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / adverse effects
Male
Melanoma* / drug therapy
Nivolumab* / administration & dosage
Nivolumab* / adverse effects
Pemphigoid, Bullous* / chemically induced
Pemphigoid, Bullous* / diagnosis
Skin Neoplasms / drug therapy
Skin Neoplasms / pathology

Substances

Antineoplastic Agents, Immunological
Cyclosporine
Immunosuppressive Agents
Nivolumab